Esperante invests EUR 500,000 to EUR 5,000,000 in syndication with other investors with an exit objective of sale or other liquidity outcomes within a period of 3 years. Our current focus for new investments is on pharmaceutical companies entering Phase 2b to Phase 3 clinical development.
Esperante does not currently invest in medical devices or digital health technologies and is not currently making new investments in diagnostics whilst continuing to fund its existing diagnostics portfolio companies.
Esperante invests in companies under the leadership of management competent in commercial partnering and transactions, private, public and non-dilutive fundraising, clinical development and regulatory management in North America and Europe and associated manufacturing expertise. Previous experience in a pharmaceutical development organisation is a prerequisite for senior management.
Esperante currently seeks to invest in companies based in Europe, North America and Israel.